Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro
M. H. Raymonda, J. H. Ciesla, M. Monaghan, J. Leach, G. Asantewaa, L. A. Smorodintsev-Schiller, M. M. Lutz, X. L. Schafer, T. Takimoto, S. Dewhurst, J. Munger, I. S. Harris
This study identifies lapatinib as a potent antiviral against SARS-CoV-2 in vitro, showing over 50,000-fold inhibition without toxicity.
bioRxiv · Nov 25, 2020Microbiology